2026 bill proposes 12-year exclusivity for FDA-regulated botanical drugs
AI Summary- U.S. lawmakers introduced a bill offering qualifying botanical drugs post-approval market exclusivity.
- 12 years of exclusivity would apply after FDA approval under the proposed legislation.
- Legacy Healthcare is raising financing for Cinainu's FDA- and PMDA-authorized Phase 3 program.